64339-95-3

Usage

Uses

Used in Pharmaceutical Industry:
(+)-DIBENZOYL-L-TARTARIC ANHYDRIDE is used as a chiral reagent for the synthesis of chiral compounds. Chiral compounds are essential in the development of pharmaceutical drugs, as they often exhibit different biological activities and selectivity compared to their non-chiral counterparts. This makes (+)-DIBENZOYL-L-TARTARIC ANHYDRIDE a valuable tool in the discovery and production of new and improved medications.
Used in Chemical Industry:
(+)-DIBENZOYL-L-TARTARIC ANHYDRIDE is used as a resolving agent for the resolution of racemic mixtures. Racemic mixtures consist of equal amounts of both enantiomers of a chiral compound, which can have different properties and effects. By using (+)-DIBENZOYL-L-TARTARIC ANHYDRIDE, chemists can separate these enantiomers, allowing for the isolation of the desired chiral compound with specific properties.
Used in Research and Development:
(+)-DIBENZOYL-L-TARTARIC ANHYDRIDE is used as a research tool for studying the properties and behavior of chiral compounds. Understanding the unique characteristics of chiral compounds can lead to advancements in various fields, such as materials science, catalysis, and pharmaceuticals. This makes (+)-DIBENZOYL-L-TARTARIC ANHYDRIDE an important compound for scientific exploration and innovation.

Upstream product

• 17026-42-5 O,O'-dibenzoyl-D-tartaric acid 
• 2743-38-6 O,O'-dibenzoyl-L-tartaric acid 
• 87-69-4 L-Tartaric acid 
• 98-88-4 benzoyl chloride 
• 47464-82-4 di-benzoyltartaric acid 
• 133-37-9 DL-tartaric acid 
• 147-71-7 D-tartaric acid 

Downstream Products

• 88009-72-7 C₃₅H₃₄NO₁₀P 
• 88009-72-7 C₃₅H₃₄NO₁₀P 
• 1013659-37-4 2,3-dibenzoyloxy D-tartaric acid mono-hydroxamate 
• 1365610-93-0 C₃₀H₃₂O₁₃ 
• 36624-61-0 (2S,3S)-2,3-bis(benzoyloxy)-4-(dimethylamino)-4-oxobutanoic acid 
• 115061-55-7 (2R,3R)-2,3-dibenzoyloxy-3-methoxycarbonylpropanoic acid 
• 88024-20-8 C₂₁H₂₁NO₇ 
• 102921-34-6 C₂₂H₂₁NO₆ 

Relevant academic research and scientific papers

Interplay of carbonyl-carbonyl, CH?O and CH?π interactions in hierarchical supramolecular assembly of tartaric anhydrides - Tartaric acid and its O-acyl derivatives: Part 11

The detailed analysis of molecular and crystal structure of the O-acyltartaric anhydrides is presented. The role of both intra- and intermolecular weak interactions is discussed. The Hirshfeld surfaces analysis in form of dnorm representation a

A L - dibenzoyl tartaric acid for the preparation of dimethyl

The invention belongs to the technical field of chemical synthesis method, in particular to a L - dibenzoyl tartaric acid for the preparation of dimethyl, the L - dibenzoyl tartaric acid for the preparation of dimethyl, comprises the following steps: S1, to L - tartaric acid, benzoyl chloride, thionyl chloride as the raw material, Lewis acid as catalyst, toluene as the solvent, through esterification, Anhydrized reaction, purification L - dibenzoyl tartaric acid [...]; S2, will be L - dibenzoyl tartaric acid [...] in pure water in the hydrolysis to obtain L - dibenzoyl tartaric acid hydrate wet product; S3, L - dibenzoyl tartaric acid hydrate the wet product in methanol and catalyst under the action of the esterification reaction, purify to get the L - dibenzoyl tartaric acid dimethyl ester. The invention the raw materials used are cheap and easy to obtain, mild reaction conditions, to recycle the methanol can be used repeatedly, after treatment is convenient, and is suitable for industrial production, it is worth.

Discovery of N-Substituted 3-Amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic Acids as Highly Potent Third-Generation Inhibitors of Human Arginase i and II

Recent efforts to identify new highly potent arginase inhibitors have resulted in the discovery of a novel family of (3R,4S)-3-amino-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid analogues with up to a 1000-fold increase in potency relative to the current standards, 2-amino-6-boronohexanoic acid (ABH) and N-hydroxy-nor-l-arginine (nor-NOHA). The lead candidate, with an N-2-amino-3-phenylpropyl substituent (NED-3238), example 43, inhibits arginase I and II with IC50 values of 1.3 and 8.1 nM, respectively. Herein, we report the design, synthesis, and structure-activity relationships for this novel series of inhibitors, along with X-ray crystallographic data for selected examples bound to human arginase II.

METHOD OF PREPARING (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE

A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.

Single-hole hollow nanospheres from enantioselective self-assembly of chiral AIE carboxylic acid and amine

Phenylacrylonitrile tartaric acids have been found to enantioselectively self-assemble with an enantiomer of a chiral amine to form either nanofibers or nanospheres that exhibit aggregation-induced emission (AIE). The nanofibers exhibited stronger emission intensity and longer wavelengths of absorption and emission than the nanospheres because of increased π-π conjugation, an effect previously unseen in AIE. When the solvent consists of a mixture of water and THF rather than water and ethanol, the resultant nanospheres have holes. The holes are the result of the dissolution of defects and a decrease in the bending energy. This is in contrast to hole formation from solvents flowing out of the nanospheres, as previously seen. Through control of the water/THF ratio, the size of the holes in the nanospheres can be tuned. Nanospheres with a single hole displayed both higher uptake capacity and larger release speed of the drug naproxen than closed nanospheres. The ability to adjust fluorescent properties of AIE molecules through the preparation of organic single-hole hollow nanospheres has also been investigated along with the implications of the AIE mechanism.

USE OF (3R)-4--3-(4-CHLOROPHENYL) BUTANOIC ACID FOR TREATING URINARY INCONTINENCE

Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence is disclosed.

Tartaric acid and its acyl derivatives. Part 5. Direct synthesis of monoacyltartaric acids and novel mono(benzoyl)tartaric anhydride: Unusual findings in tartaric acid acylation

Practical acylation of unprotected tartaric acid 1 by acyl chlorides to the corresponding monoacyltartaric acids 2 has been shown. Several unusual cases in the acylation of 1 are observed; it has been found that two routes of acylation are possible. In the benzoylation of 1, in addition to the expected products, the formation of a previously undescribed monobenzoyltartaric anhydride 7a is reported. An unusual DME cleavage during the course of acylation was also observed. ARKAT USA, Inc.

Chiral recognition based on enantioselectively aggregation-induced emission

(Figure Presented) Novel chiral AIE compounds bearing a tartaric acid group were synthesized. They selectively aggregated with one enantiomer of a number of chiral amines, such that one enantiomer led to strong fluorescence and another enantiomer showed no or only weak fluorescence. This was used for the quantitative analysis of enantiomeric composition.

Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use

Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.